Summary
Calcium carbonate has been successfully used as a phosphate binder in patients with chronic renal failure; however, a high frequency of hypercalcaemia has been reported. To study the effects of calcium carbonate preparations with different dissolution characteristics on the incidence of this side effect, we conducted a double-blind, crossover trial in 21 patients undergoing chronic haemodialysis. Aluminium hydroxide therapy was replaced with calcium carbonate. The subjects then randomly received either an enteric-coated or a gastric-coated preparation. Calcium carbonate (3.1–3.6 g/d) controlled serum phosphate concentrations as effectively as aluminium hydroxide (2.9 g/d). Concurrently, there was a significant rise in mean serum calcium and a fall in serum concentrations of both parathyroid hormone and osteocalcin, the latter suggesting a decrease in bone turnover. Overall, hypercalcaemic episodes developed in 9 patients (43%) and occurred at a considerable frequency (33 episodes per 100 patient-months) during treatment with the gastric-coated formulation. Following conversion to enteric-coated calcium carbonate (3.6 g/d) patients had fewer occurrences of hypercalcaemia (12 episodes per 100 patient-months,P<0.05) and, as compared to the gastric-coated preparation, increases in serum calcium >3.00 mmol/l were not observed at all. Hyperaluminaemia was regressive during therapy with calcium carbonate, but addition of small doses of aluminium hydroxide caused a large rise in serum aluminium concentrations after infusion of desferrioxamine, indicating an enhanced rate of absorption or aberrant compartmentalization of aluminium.
We conclude that calcium carbonate can control hyperphosphataemia in dialysis patients. However, undesirable hypercalcaemic episodes may occur, the frequency and severity of which can be lowered by the use of an enteric-coated preparation. Concomitant use of aluminium hydroxide and calcium carbonate should be restricted to patients in whom the degree of aluminium accumulation is monitored by serial desferrioxamine tests.
Similar content being viewed by others
References
Alfrey AC (1983) Aluminum. Adv Clin Chem 23:69–91
Alfrey AC, Sedman A, Chan YL (1985) The compartmentalization and metabolism of aluminum in uremic rats. J Lab Clin Med 105:227–233
Alon U, Davidai G, Bentur L, Berant M, Better OS (1986) Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320–325
Andress DL, Ott SM, Maloney NA, Sherrard DJ (1985) Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468–473
Andress DL, Kopp JB, Maloney NA, Coburn JW, Sherrard DJ (1987) Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 316:292–296
Breuer J, Moniz C, Baldwin D, Parsons V (1987) The effect of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transplant 2:347–350
Canavese C, Thea A, Pacitti A, Salomone M, Mangiarotti G, Segoloni G, Stratta P, Gurioli L, Costantini S, Giordini R, Vercellone A (1989) Prevention and treatment of aluminum overload in uremic patients: long-term results. Clin Nephrol 31:169–174
Clark AGB, Oner A, Ward G, Turner C, Rigden SPA, Haycock GB, Chantler C (1989) Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 4:539–544
Feinfeld DA, Sherwood LM (1988) Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int 33:1049–1058
Fordtran JS, Locklear TW (1966) Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 11:503–521
Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M (1986) Calcium carbonate, an aluminium-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 29:S-114–S-119
Froment DPH, Molitoris BA, Buddington B, Miller N, Alfrey AC (1989) Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 36:978–984
Henrich WL, Hunt JM, Nixon JV (1984) Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 310:19–23
Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, Sherrerd DJ, Coburn JW (1986) Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 12:314–319
Ittel TH, Buddington B, Miller NL, Alfrey AC (1987) Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 32:821–826
Ittel TH, Kluge R, Sieberth HG (1988) Enhanced gastrointestinal absorption of aluminium in uraemia: time course and effect of vitamin D. Nephrol Dial Transplant 3:617–623
Ittel TH, Hofstädter F, Gladziwa U, Sieberth HG (1989) Reduced deposition of aluminium in trabecular bone of uraemic rats treated with dihydroxylated vitamin D metabolites. Nephrol Dial Transplant 4:957–965
Ittel TH, Griessner A, Sieberth HG (1990) Effect of lactate on the absorption and retention of aluminum in the remnant kidney rat model. Nephron (in press)
Kaye M (1983) Oral aluminum toxicity in a non-dialyzed patient with renal failure. Clin Nephrol 20:208–211
Kaye M, Barber E, Vasilevsky M, Langer K (1989) Calcium-free dialyzate: development and applications. Clin Nephrol 31:132–138
Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z (1987) Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 28:222–226
Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS (1989) Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690–695
Malberti F, Surian M, Mercantini F, Marchini M (1988) Effects of dialysate calcium concentration changes on plasma calcium and parathyroid hormone in dialysis patients treated with calcium carbonate as a phosphate binder. Nephrol Dial Transplant 3:565
Maynard JC, Cruz C, Kleerekoper M, Levin NW (1986) Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 104:358–361
Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J (1985) Comparison of 1αOH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39:309–315
Morinière PH, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine CH, Marie A, Leflon P, Roche D, Fournier A (1988) Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralization. Nephrol Dial Transplant 3:651–656
Morinière PH, Boudailliez B, Hocine CH, Belbrik S, Renaud H, Westeel PF, Cohen-Solal M, Fournier A (1989) Prevention of osteitis fibrosa, aluminium bone disease and soft tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium+Mg(OH)2 vs Al(OH)3±1alphaOHvitamin D3. Nephrol Dial Transplant 4:1045–1053
Morinière P, Cohen-Solal M, Bebrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL, Fournier A (1989) Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53:93–101
O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V (1986) Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet I:880–882
Oe PL, Lips P, Van der Meulen J, De Vries PMJ, Van Bronswijk H, Donker AJM (1987) Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 28:180–185
Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS (1986) The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30:753–759
Renaud H, Atik A, Hervé M, Morinière P, Hocine C, Belbrik S, Fournier A (1988) Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 48:28–32
Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J (1989) High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 4:105–109
Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS (1989) Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110–1113
Schneider HW, Kulbe KD, Weber H, Streicher E (1986) In vitro and in vivo studies with a non-aluminum phosphate-binding compound. Kidney Int 29:S120-S123
Sedman AB, Wilkening GN, Warady BA, Lum GM, Alfrey AC (1984) Encephalopathy in childhood secondary to aluminum toxicity. J Pediatr 105:836–838
Sheikh MS, Ramirez A, Emmett M, Santa Ana C, Schiller LR, Fordtran JS (1988) Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium. J Clin Invest 81:126–132
Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS (1989) Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 83:66–73
Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J (1986) Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157–161
Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J (1989) Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897–903
Smith AJ, Faugere MC, Abreo K, Fanti P, Julian B, Malluche HH (1986) Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6:275–283
Williams B, Vennegoor M, O'Nunan T, Walls (1989) The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure. Nephrol Dial Transplant 4:725–729
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ittel, T.H., Schäfer, C., Schmitt, H. et al. Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 69, 59–67 (1991). https://doi.org/10.1007/BF01666818
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01666818